Volitionrx (VNRX) Other Non-Current Liabilities (2020 - 2025)

Volitionrx (VNRX) posted Other Non-Current Liabilities of $112770.0 for Q3 2025, down 19.8% on a QoQ basis from $140612.0 in Q2 2025.

Volitionrx (VNRX) Other Non-Current Liabilities (2020 - 2025) Analysis & Trends

Volitionrx's Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $112770.0 for Q3 2025.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $112770.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $112770.0 (changed N/A YoY) and the FY2023 annual result came in at $126649.0, changed N/A from the prior year.
Other Non-Current Liabilities was $112770.0 for Q3 2025 at Volitionrx, down from $140612.0 in the prior quarter.
Across five years, Other Non-Current Liabilities topped out at $140612.0 in Q2 2025 and bottomed at $55404.0 in Q2 2021.
A 4-year average of $84936.9 and a median of $66626.0 in 2021 frame the typical range for Other Non-Current Liabilities.
Peak annual rise in Other Non-Current Liabilities reached 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
Volitionrx's Other Non-Current Liabilities stood at $55404.0 in 2021, then changed by 0.0% to $55404.0 in 2022, then surged by 128.59% to $126649.0 in 2023, then retreated by 10.96% to $112770.0 in 2025.
Business Quant data shows VNRX's Other Non-Current Liabilities at $112770.0 in Q3 2025, $140612.0 in Q2 2025, and $77848.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Volitionrx	109,643.10	-2.35 Mn	-

Download Data